{"page_content": "ESG Report 2023\nAccess to Medicines  and Affordable Pricing Strategy\nDescription of actions and initiatives to promote access to health care \nproducts for priority diseases and in priority countries as defined by the Access to Medicine Index\n \nSASB: HC-BP-240A.1\nOur goal is for as many eligible patients as possible to have access to our \nmedicines and for out-of-pocket costs for the individual patients to be as reasonable as possible.\nU.S. Access Program for PYRUKYND\u00ae\nPYRUKYND\u00ae (mitapivat) was approved by the U.S. Food and Drug Administration in February 2022. Since approval, \n88% of eligible U.S. patients  \nwith commercial health insurance have utilized the PYRUKYND\u00ae Copay Program which lowers copay costs to\n $0 per prescription.\nEligible U.S. patients who are uninsured, underinsured, or rendered uninsured may get help from our \nPatient Assistance Program  which offers  free \nprescriptions.\nWe developed myAgios\u00ae Patient Support Services in close collaboration  \nwith the patient, caregiver and provider communities. Through myAgios\u00ae,  \nwe provide:\n\u2022   A single point of engagement for patients and prescribers  \nfor prescription and access support\n\u2022   Dedicated, clinically trained patient support managers \n\u2022   Disease education for patients and their caregivers\u2022   Support for patients and caregivers to navigate access to treatment \nregardless of their insurance carrier or coverage status\n\u2022   Customized adherence support \n\u2022   Opportunities to connect with the patient communityNathan,  \nliving with PK deficiency\nMore details can be found at  PYRUKYND.myagios.com  \n13", "metadata": {"source": "NASDAQ_AGIO_2022.pdf", "page": 12, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}